Waverley Pharma (TSXV:WAVE) Float Percentage Of Total Shares Outstanding : 0.00% (As of Jun. 14, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Waverley Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Waverley Pharma's float shares is 0.00 Mil. Waverley Pharma's total shares outstanding is 54.00 Mil. Waverley Pharma's float percentage of total shares outstanding is 0.00%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Waverley Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Waverley Pharma's Institutional Ownership is 2.53%.

Waverley Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Waverley Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	0.00	/	54.00
	=	0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Waverley Pharma (TSXV:WAVE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Waverley Pharma Inc (TSXV:WAVE) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

5GZ:Germany

Address

1250 Waverley Street, Suite 4, Winnipeg, MB, CAN, R3T 6C6

Website

https://www.waverleypharma.com

Waverley Pharma Inc is a biopharmaceutical company. It is engaged in the research, development, and commercialization of human therapeutics that focuses on oncology. The company products pipeline includes Capecitabine and Temozolomide, among others.

Executives

Albert David Friesen

10% Security Holder, Director, Senior Officer